

Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.  
A32737 072396.0225

Serial No.  
09/844,915

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Applicant  
Robbins et al.

Filing Date  
April 27, 2001

Group Art Unit  
1633 1135

**RECEIVED**

FEB 26 2002

TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENT**

Document No.	Date	Country	Class	SubClass	Translation Yes No
9 5 3 5 0 3 2	12/28/95	WIPO			

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

Liang et al. "Phenotype and allostimulatory function of dendritic cells treated with antisense oligonucleotides targeting CD80 or CD86 mRNA," Transplantation Proceedings, Vol. 33, No. 1-2 p. 235.
Takayama et al. "Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potentially tolerogenic antigen-presenting cells". Transplantation Vol. 68, No. 12, pp.1903-1909, Dec. 1999.
Thomson et al. "Are dendritic cells the key to liver transplant tolerance?" Immunology Today, Vol. 20, No. 1, pp.27-32, Jan. 1999.

NY02 369117.1

1

Examiner

Date Considered

11/20/02

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT


(Use several sheets if necessary)

Applicant  
Robbins et al.

Filing Date  
April 27, 2001

Group Art Unit  
1637 1635

RECEIVED  
DEC 27 2001  
TECH CENTER 1600/2600



Ranieri *et al.*, "Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination," *J. Virol.* 73:10416-10425 (1999).

Rea *et al.*, "Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset," *J. Virol.* 73:10245-10253 (1999).

Thomson and Lu, "Dendritic cells as regulators of immune reactivity: implications for transplantation," *Transplantation* 68:1-8 (1999).

Tuting *et al.*, "Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity," *J. Gene Med.* 1:400-406 (1999).

Banchereau and Steinman, "Dendritic cells and the control of immunity," *Nature* 392:245-252 (1998).

Khanna *et al.*, "Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow," *Transplantation* 65:479-485 (1998).

Lee *et al.*, "Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta," *Transplantation* 66:1810-1817 (1998).

Lu *et al.* *Journal of Leukocyte Biology* Supplement 2 Abstract#B52 (1998).

Rescigno *et al.*, "Dendritic cell survival and maturation are regulated by different signaling pathways," *J. Exp. Med.* 188:2175-2180 (1998).

Lu *et al.*, "Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival," *Transplantation* 64:1808-1815 (1997).

Fu *et al.*, "Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts," *Transplant Proc.* 29:1310 (1997).

Fu *et al.*, "Costimulatory molecule-deficient dendritic cell progenitors (MHC class II<sup>-</sup>, CD80dim, CD86<sup>-</sup>) prolong cardiac allograft survival in nonimmunosuppressed recipients," *Transplantation* 62:659-665 (1996).

NY02 361185 1

2

Examiner

Date Considered

11/20/02

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Applicant  
Robbins et al.

Filing Date  
April 27, 2001

Group Art Unit  
1633 1635

(Use several sheets if necessary)



Lu et al., "Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis," <i>J. Immunol.</i> <u>157</u> :3577-3586 (1996).
Lu et al., "Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes," <i>Transplantation</i> <u>60</u> :1539-1545 (1995).
Rastellini et al., "Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival," <i>Transplantation</i> <u>60</u> :1366-1370 (1995).
Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Res.</i> <u>19</u> :2499 (1991).
Jolly, D., "Viral vector systems for gene therapy," <i>Cancer Gene Therapy</i> , 1:51-64. (1994).
Starzl et al., "The biological basis of and strategies for clinical xenotransplantation," <i>Immunological Reviews</i> <u>141</u> :213 (1994).
Woo et al., "Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells," <i>Transplantation</i> <u>58</u> :848 (1994).
Berkner, K.L., "Expression of heterologous sequences in adenoviral vectors," <i>Curr. Top. Micro Immunol.</i> <u>158</u> :39-66. (1992).
Inaba et al., "Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor," <i>J. Exp. Med.</i> <u>176</u> :1693-1702 (1992).
Horwitz, M.S., "Adenoviridae and Their Replication," in <i>Virology</i> , 2nd edition. Fields et al., eds., Raven Press, New York, 1990
Billiar et al., "An L-arginine-dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro," <i>J. Exp. Med.</i> <u>169</u> :1467-1472 (1989).

Examiner

Date Considered

11/20/02

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**


(Use several sheets if necessary)

Applicant  
Robbins et al.

Filing Date  
April 27, 2001

Group Art Unit  
1633 1635

RECEIVED  
DEC 27 2001  
TECH CENTER 1600/2900



**U.S. PATENT DOCUMENTS**

*Exam. Init.	Document No.								Date	Name	Class	Subclass	Filing Date if Appropriate
JS		5	8	7	1	7	2	8	2 16 99	Thomson et al.			

**FOREIGN PATENT DOCUMENT**

Document No.								Date	Country	Class	SubClass	Translation Yes No	

**OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)**

JS		Hirano <i>et al.</i> , "Graft hyporeactivity induced by immature donor-derived dendritic cells," <i>Transplant Proc.</i> 32:260-264 (2000)
		Gao <i>et al.</i> , "CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection," <i>Immunology</i> 98:159-170 (1999).
		Lee <i>et al.</i> , "Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B," <i>Transplantation</i> 68:1255-1263 (1999).
		Lu <i>et al.</i> , "Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4lg)," <i>J. Leukoc. Biol.</i> 66:293-296 (1999)
JS		Lu <i>et al.</i> , "Adenoviral delivery of CTLA4lg into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients," <i>Gene Ther.</i> 6:554-563 (1999).

NO-2 361185

1

Examiner

*Lee*

Date Considered

11/20/02

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.